EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 34 / Numéro 10 (Octobre 2018) Med Sci (Paris), 34 10 (2018) 824-832 Références
Open Access
Numéro
Med Sci (Paris)
Volume 34, Numéro 10, Octobre 2018
Page(s) 824 - 832
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2018208
Publié en ligne 19 novembre 2018
  1. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. Inhal Toxicol 2014 ; 26 : 811–828. [PubMed] [Google Scholar]
  2. Wilson JMG, , Jungner G. Principles and practice of screening for disease 1968 ; Geneva, World Health Organisation, 164 p [Google Scholar]
  3. Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008 ; 86 : 317–319. [CrossRef] [PubMed] [Google Scholar]
  4. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 2013 ; 4 : 627–635. [Google Scholar]
  5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007 ; 357 : 1579–1588. [Google Scholar]
  6. Stieber P, Nagel D, Blankenburg I, et al. Diagnostic efficacy of CA 15–3 and CEA in the early detection of metastatic breast cancer: a retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta 2015 ; 448 : 228–231. [Google Scholar]
  7. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 ; 324 : 1156–1161. [Google Scholar]
  8. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 ; 360 : 1310–1319. [Google Scholar]
  9. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 ; 360 : 1320–1328. [Google Scholar]
  10. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2017 ; 167 : 449–455. [CrossRef] [PubMed] [Google Scholar]
  11. Chen JS, Chen KT, Fan WC, et al. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin Chem Lab Med 2010 ; 48 : 719–725. [PubMed] [Google Scholar]
  12. Song LL, Li YM. Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests. World J Gastrointest Oncol 2016 ; 8 : 793–800. [CrossRef] [PubMed] [Google Scholar]
  13. Dhaliwal A, Vlachostergios PJ, Oikonomou KG, et al. Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives. World J Gastrointest Oncol 2015 ; 7 : 178–183. [CrossRef] [PubMed] [Google Scholar]
  14. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004 ; 351 : 2704–2714. [Google Scholar]
  15. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014 ; 370 : 1287–1297. [Google Scholar]
  16. NCI dictionary of cancer terms Natl Cancer Inst nd. https://www.cancer.gov/publications/dictionaries/cancer-terms. [Google Scholar]
  17. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. CR Seances Soc Biol Fil 1948 ; 142 : 241–243. [Google Scholar]
  18. Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987 ; 23 : 707–712. [CrossRef] [PubMed] [Google Scholar]
  19. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 2016 ; 35 : 347–376. [CrossRef] [PubMed] [Google Scholar]
  20. Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014; 2 : 107. [Google Scholar]
  21. Wan JCM, Massie C, , Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017 ; 17 : 223–238. [Google Scholar]
  22. Mouliere F, El Messaoudi S, Pang D, et al. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol 2014 ; 8 : 927–941. [CrossRef] [PubMed] [Google Scholar]
  23. Church TR, Wandell M, , Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014 ; 63 : 317–325. [CrossRef] [PubMed] [Google Scholar]
  24. Lamb YN, Dhillon S. Epi proColon® 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther 2017 ; 21 : 225–232. [Google Scholar]
  25. Rasmussen SL, Krarup HB, Sunesen KG, et al. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One 2017 ; 12 : e0180809. [CrossRef] [PubMed] [Google Scholar]
  26. Rahier JF, Druez A, Faugeras L, et al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin Epigenetics 2017 ; 9 : 53. [Google Scholar]
  27. Jiang T, Zhai C, Su C, et al. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 2016 ; 100 : 63–70. [CrossRef] [PubMed] [Google Scholar]
  28. Lin Z, Neiswender J, Fang B, et al. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget 2017 ; 8 : 26625–26636. [CrossRef] [PubMed] [Google Scholar]
  29. Zhou Q, Li W, Leng B, et al. Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis. PLoS One 2016 ; 11 : e0155495. [CrossRef] [PubMed] [Google Scholar]
  30. Hosgood HD, Liu CS, Rothman N, et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis 2010 ; 31 : 847–849. [CrossRef] [PubMed] [Google Scholar]
  31. Thyagarajan B, Wang R, Barcelo H, et al. Mitochondrial copy number is associated with colorectal cancer risk. Cancer Epidemiol Prev Biomarkers 2012 ; 21 : 1574–1581. [CrossRef] [Google Scholar]
  32. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australasian Med J 1869 ; 14 : 146–147. [Google Scholar]
  33. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009 ; 15 : 6980–6986. [CrossRef] [PubMed] [Google Scholar]
  34. Fiorelli A, Accardo M, Carelli E, et al. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis. Ann Thorac Surg 2015 ; 99 : 1899–1905. [Google Scholar]
  35. Ilie M, Hofman V, , Long-Mira E, et al. Sentinel circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014 ; 9 : e111597. [CrossRef] [PubMed] [Google Scholar]
  36. Wang L, Wu C, Qiao L, et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer. J Cancer 2017 ; 8 : 104–110. [CrossRef] [PubMed] [Google Scholar]
  37. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 ; 32 : 579–586. [CrossRef] [PubMed] [Google Scholar]
  38. Freidin MB, Freydina D V, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem 2015 ; 61 : 1299–1304. [CrossRef] [PubMed] [Google Scholar]
  39. Alix-Panabières C, , Pantel K. Characterization of single circulating tumor cells. FEBS Lett 2017 ; 591 : 2241–2250. [CrossRef] [PubMed] [Google Scholar]
  40. Roth C, Rack B, , Müller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010 ; 12 : R90. [CrossRef] [PubMed] [Google Scholar]
  41. Kodahl AR, Lyng MB, Binder H, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014 ; 8 : 874–883. [CrossRef] [PubMed] [Google Scholar]
  42. Tomasetti M, Amati M, Neuzil J, et al. Circulating epigenetic biomarkers in lung malignancies: from early diagnosis to therapy. Lung Cancer 2017 ; 107 : 65–72. [CrossRef] [PubMed] [Google Scholar]
  43. Adams DL, Adams DK, Alpaugh RK, et al. Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions. Cancer Epidemiol Prev Biomarkers 2016 ; 25 : 1037–1042. [CrossRef] [Google Scholar]
  44. Gonzalez RM, Daly DS, Tan R, et al. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 2011 ; 20 : 1543–1551. [Google Scholar]
  45. Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer. Cancer Metastasis Rev 2017 : 1–10. [Google Scholar]
  46. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9 : eaan2415. [Google Scholar]
  47. Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine 2016 ; 10 : 117–123. [CrossRef] [PubMed] [Google Scholar]
  48. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; eaar3247. [Google Scholar]
  49. Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017 ; 377 : 513–522. [Google Scholar]
  50. Mouliere F, Robert B, Peyrotte EA, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011 ; 6 : e23418. [CrossRef] [PubMed] [Google Scholar]
  51. Leszinski G, Lehner J, Gezer U, et al. Increased DNA integrity in colorectal cancer. In Vivo (Brooklyn) 2014 ; 28 : 299–303. [PubMed] [Google Scholar]
  52. Thierry A, Messaoudi SE. Methods for screening a subject for cancer. WO2016/063122. [Google Scholar]
  53. Wang M, Ji S, Shao G, et al. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol 2017: 1–6. [PubMed] [Google Scholar]
  54. Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Ther Adv Urol 2014 ; 6 : 74–77. [CrossRef] [PubMed] [Google Scholar]
  55. Jordan B. Dépister les cancers asymptotiques ?. Med Sci (Paris) 2018 ; 34 : 363–365. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.